Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-Up
Min Wang(Zhongshan People's Hospital), Weijia Wang(Zhongshan People's Hospital), M. Wada(Nicolaus Copernicus Astronomical Center), Shanzhi He(Zhongshan People's Hospital), Kevin G. Pinz(Unknown), Ling Ding(Qiqihar University), Yu Ma(Io Therapeutics (United States)), Yupo Ma(Macau University of Science and Technology), Mingxia Wang(Hebei Medical University), Chanjuan Zou(Zhongshan People's Hospital), Ronghao Zeng(Zhongshan People's Hospital), Nicole Hershkowitz(Long Island University), V. Destéfano(Io Therapeutics (United States)), Ming Hong(Guangzhou University of Chinese Medicine)
Cited by 9
Related Papers
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
|Annals of the Rheumatic Diseases|2024|194
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
|Oncotarget|2016|112
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
|Journal of Virology|2016|81
Stem Cell Gene SALL4 Suppresses Transcription through Recruitment of DNA Methyltransferases
|Journal of Biological Chemistry|2011|71
Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4
|Journal of Hematology & Oncology|2011|57